S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMPL stock logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

IMPL Stock News Headlines

Impel Pharmaceuticals Inc. (IMPLQ)
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Biotech Catches Major Premarket Bid
84P.SG - Impel Pharmaceuticals Inc
Impel Pharmaceuticals Inc. (IMPL)
Impel Pharmaceuticals gets new CFO
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%

Debt

Sales & Book Value

Annual Sales
$20.99 million
Book Value
($1.86) per share

Miscellaneous

Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Leonard S. Paolillo (Age 44)
    Interim President & CEO
    Comp: $523.97k
  • Dr. John D. Hoekman Ph.D. (Age 42)
    Co-Founder and Chief Technology & Development Officer
  • Mr. Michael W. Kalb CPA (Age 52)
    Chief Financial Officer
  • Ms. Jennifer L. Berman
    Vice President of Marketing
  • Ms. Sarah Wille
    Vice President of Human Resources
  • Dr. Lynn C. Gold Ph.D. (Age 66)
    Senior Vice President of Regulatory
  • Mr. Scott Youmans (Age 56)
    Senior Vice President of Technical Operations

IMPL Stock Analysis - Frequently Asked Questions

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) released its earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.42. The company earned $0.09 million during the quarter.

When did Impel Pharmaceuticals IPO?

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

This page (NASDAQ:IMPL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners